Skip to main content

Table 3 Final disease activity parameters achieved in different ILAR categories during one year etanercept treatment

From: Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia

JIA subtype ACR Pedi, % Inactive disease, %
ACR Pedi 30 ACR Pedi 50 ACR Pedi 70 ACR Pedi 90
All patients (n = 197) 90,9 89,8 85,3 68,5 67
Persistent oligoarticular (n = 84) 90,5 90,5 88,1 77,4 86,9
Extended oligoarticular (n = 23) 95,7 95,7 95,7 73,9 65,2
Polyarticular RF negative (n = 64) 90,6 87,5 85,4 57,8 45,3
Polyarticular RF positive (n = 1) 100 100 0 0 0
Psoriatic (n = 1) 100 100 100 100 100
Enthesitis-related (n = 24) 87,5 87,5 83,3 62,5 58,3
  1. n number, RF rheumatoid factor, JADAS-71 juvenile arthritis disease activity score 71; inactive disease defined by Wallace criteria